[68Ga]Ga-EMP-100 临床前 PET 表征用于 NSCLC 的 c-Met 无创评估
本研究对靶向 c-Met 的 PET 示踪剂 [68Ga]Ga-EMP-100 进行放射标记与表征,并在不同组织学亚型的 NSCLC 细胞衍生异种移植(CDX)模型中进行 PET/CT 显像。结果显示该示踪剂放射化学产率与纯度均高、主要经肾排泄,PET/CT 可无创区分模型间 c-Met 表达水平;SUVmax 与 EP1454Y 抗体的 c-Met 表达呈良好相关,而 MET 基因改变与细胞表面 c-Met 蛋白表达不相关。
要点
- [68Ga]Ga-EMP-100 自动化标记产率与纯度均高,主要经肾排泄。
- PET/CT 可无创区分 CDX 模型的 c-Met 表达水平,H1648 与 EBC-1 摄取最高。
- SUVmax 与 EP1454Y 抗体 c-Met 表达良好相关,MET 基因改变与蛋白表达不相关。
核心结论
- [68Ga]Ga-EMP-100 PET/CT 可在体内定量 c-Met 表达,补充传统 IHC 与遗传学方法。
- 该示踪剂有望用于 NSCLC 中 c-Met 靶向治疗的患者筛选与疗效监测,尚需进一步临床研究。
研究设计与样本
- 本研究为临床前研究,对 [68Ga]Ga-EMP-100 进行放射标记与表征,并构建不同特征的 NSCLC CDX 模型进行 PET/CT 显像。
- 肿瘤摄取与异质性经量化后,与 IHC(SP44 和 EP1454Y 抗体的 H-score)及 FISH 和 NGS 检测的 MET 基因扩增进行比较。
主要发现
- 自动化放射标记的 [68Ga]Ga-EMP-100 显示高放射化学产率(RCY)与纯度(RP)。
- 药代动力学研究显示主要经肾途径快速排泄。
- PET/CT 显像对比度高,可无创对 CDX 模型的 c-Met 受体水平进行分类。
- H1648 与 EBC-1 模型的肿瘤摄取最高。
- MET 基因改变与细胞表面 c-Met 蛋白表达不相关,但使用 EP1454Y 抗体时 SUVmax 与 c-Met 表达呈良好相关。
关键数值与推荐
- IHC 采用 SP44 和 EP1454Y 抗体以 H-score 评估 c-Met 表达。
- MET 基因扩增通过 FISH 和 NGS 检测。
临床怎么用
- 该示踪剂可作为无创工具用于 NSCLC 中 c-Met 靶向治疗的患者筛选与疗效监测的潜在手段。
局限性
- 本研究为临床前 CDX 模型研究,结论需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The c-Met receptor is a key therapeutic target in non-small cell lung cancer (NSCLC). Current methods for assessing c-Met level, are limited by biopsy sampling, which fails to account for spatio-temporal and intra-tumour heterogeneity. This study aims to evaluate the use of PET/CT imaging for non-invasive, full-body quantification of c-Met expression in different subtypes of NSCLC, encompassing both ADC and squamous cell carcinoma and compare it to MET gene alterations and IHC c-Met scoring. RESULTS: [68Ga]Ga-EMP-100, a PET radiotracer targeting c-Met, was radiolabelled and characterized. Cell-Derived Xenograft (CDX) models of NSCLC with different characteristics were developed and validated for PET/CT imaging using [68Ga]Ga-EMP-100. Tumour uptake and heterogeneity were quantified and compared to c-Met expression determined by IHC (H-score using SP44 and EP1454Y antibodies) and MET gene amplification detected by FISH and NGS. Automated radiolabelling of [68Ga]Ga-EMP-100 demonstrated a high radiochemical yield (RCY) and purity (RP). Pharmacokinetics studies revealed rapid excretion predominantly by the renal pathway. PET/CT imaging resulted in high contrast and enabled non-invasive classification of CDX models regarding c-Met receptor levels. The highest tumour uptake was observed in H1648 and EBC-1 models. Although MET gene alterations were not correlated with c-Met protein expression at the cell surface, a good correlation was found between SUVmax and c-Met expression, when using the EP1454Y antibody. CONCLUSION: PET/CT imaging using [68Ga]Ga-EMP-100 successfully quantified c-Met expression in vivo, clearly adding up to conventional IHC and genetic methods. Our study adds novel comparative evidence across tumour histotypes, providing new insight into how tumour phenotype affects c-Met-targeted imaging. This radiotracer holds potential as a non-invasive tool for selecting patients for c-Met-targeted therapies and monitoring therapeutic response in NSCLC. Further clinical studies are warranted.
引用
- Rusu T, Rodenas A, Capet L, et al. Preclinical PET characterization of [68Ga]Ga-EMP-100 for non-invasive assessment of c-Met in NSCLC. EJNMMI Res. 2026. PMID: 42481881. doi:10.1186/s13550-026-01483-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。